Genmab falls after 'uneventful' Q1, profit miss

Genmab A/S

08/05/2026 12:02

** Shares in Denmark's Genmab GMAB.CO fall around 10% despite the biotech firm's Q1 report showing only a slight miss on the profit line

** Q1 operating profit came to $180 million vs. IBES estimate $184.7 million

** Jefferies deems Q1 as "uneventful" as outlook was also reiterated

** "Numbers don't lie, but a 10% drop in the share price was a harsh assessment, in my opinion," Nordnet analyst Per Hansen says

** Hansen notes that the U.S. market reaction on the parallel listing was moderate but also on the negative side on Thursday

** He says the reporting was largely made up of "known quantities", as partners have already reported, with cancer drug Darzalex continuing as expected

** The shares hit the bottom of Europe's STOXX 600 index .STOXX and are on track for their worst day since January 2020 if the losses hold

(Reporting by Elviira Luoma)

((Elviira.luoma@thomsonreuters.com))